Key factors
symPRNB
exchUS
MCap3.325B
Beta0.859
EPS-0.09
Div date0000-00-00
Yesterday
symPRNB
exchUS
50 Day MA100.10
200 Day MA74.18
52 Week High101.89
52 Week Low28.3
Target Price 86.0
Market Cap Mln3325.28
Share statistics
Shares Outstanding33.23M
Shares Float26.61M
Percent Institutions100.78
PercentInsiders1.39
SharesShort1581.54K
Short Ratio0.5
Shares Short Prior Month2004.25K
Short Percent6.480
Short Percent Float6.480
Short Percent Outstanding5.000
Revenue TTM 50.0M
Revenue Per Share TTM 1.647
Quarterly Revenue Growth YOY 66.69
Gross Profit TTM 35.16M
EBITDA6898.0K
Diluted Eps TTM-2.27
Quarterly Earnings Growth YOY10.70
earning
Operating Margin TTM -1.48
EPS Estimate Current Year -3.65
EPS Estimate Next Year -5.22
Earnings Share -0.09
Dividend
Dividend Date0000-00-00
Last Split Date 0000-00-00
business
Enterprise Value Revenue60.40
Book Value /share 10.59
Price Book MRQ 9.452
Price Sales TTM 60.66
ProfitMargin -1.37
ReturnOnAssetsTTM -0.16
ReturnOnEquityTTM-0.26
Gic GroupPharmaceuticals, Biotechnology & Life Sciences
Gic IndustryBiotechnology
Gic Sector Health Care
Gic Sub Industry Biotechnology
IndustryBiotechnology
SectorHealthcare
CIK 0001510487
Code PRNB
CUSIP 74257L108
Employer Id Number 26-3487603
CountryISO US
Currency CodeUSD
Currency Name US Dollar
Exchange NASDAQ
Currency Symbol $
Type Common Stock
UpdatedAt 2020-10-08
Home Category Domestic
Fiscal Year End December
Full Time Employees124.0
IPODate 2018
International Domestic Domestic
MostRecent Quarter2020-06-30
Contact
NamePrincipia Biopharma Inc
Address220 East Grand Avenue, South San Francisco, CA, United States, 94080
Country NameUSA
Phone650 416 7700
Web URLwww.principiabio.com
Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immune-mediated diseases. The company is developing rilzabrutinib, an inhibitor that is in Phase III clinical trials for the treatment of pemphigus, a chronic skin disease, as well as and pemphigus foliaceus; in a Phase 1/2 trial for the treatment of immune thrombocytopenia; and a Phase 2 trial for the treatment of IgG4-related disease. It is also developing PRN2246/SAR442168, an inhibitor, which is in Phase Ii clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; and PRN473, a drug candidate that is in Phase I clinical trial for the treatment of immune-medicated diseases. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California. As of September 25, 2020, Principia Biopharma Inc. operates as a subsidiary of Sanofi.